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The unfolded protein response (UPR), induced by
endoplasmic reticulum (ER) stress, regulates the
expression of factors that restore protein folding
homeostasis. However, in the liver and kidney, ER
stress also leads to lipid accumulation, accompanied
at least in the liver by transcriptional suppression of
metabolic genes. The mechanisms of this accumu-
lation, including which pathways contribute to the
phenotype in each organ, are unclear. We combined
gene expression profiling, biochemical assays, and
untargeted lipidomics to understand the basis of
stress-dependent lipid accumulation, taking advan-
tage of enhanced hepatic and renal steatosis in
mice lacking the ER stress sensor ATF6a. We found
that impaired fatty acid oxidation contributed to the
early development of steatosis in the liver but not
the kidney, while anorexia-induced lipolysis pro-
moted late triglyceride and free fatty acid accumula-
tion in both organs. These findings provide evidence
for both direct and indirect regulation of peripheral
metabolism by ER stress.
INTRODUCTION
Endoplasmic reticulum (ER) stress is caused by an imbalance
between the need to properly fold newly synthesized secretory
and membrane proteins and the capacity of the organelle to
do so. Accordingly, unfolded protein response (UPR) activation1794 Cell Reports 19, 1794–1806, May 30, 2017 ª 2017 The Authors
This is an open access article under the CC BY-NC-ND license (http://alleviates ER stress by both transcriptional and non-transcrip-
tional mechanisms that, together, diminish protein load and
enhance the ability of the organelle to properly fold, transport,
or degrade client proteins (Walter and Ron, 2011; Wang and
Kaufman, 2016). As ER protein folding is a fundamental cellular
process, the upregulation of genes encoding ER chaperones,
trafficking factors, and ER-associated degradation (ERAD) com-
ponents is conserved from one cell type to another and from
yeast to humans (Arensdorf et al., 2013b).
In the liver, ER stress leads to lipid accumulation, or hepatic
steatosis (Rutkowski et al., 2008; Yamamoto et al., 2010; Zhang
et al., 2011), indicating that ER stress and/or UPR activation
regulates, directly or indirectly, lipid metabolism in that organ.
This steatosis can be elicited by overexpression of a difficult-
to-fold protein (Rutkowski et al., 2008); proteasome inhibition
(Chikka et al., 2013); or, most robustly, inhibition of the ER-spe-
cific post-translational modification N-linked glycosylation using
the drug tunicamycin (TM) (Lee et al., 2012; Rutkowski et al.,
2008). Necessarily, ER stress must elicit hepatic steatosis by
decreased lipid efflux or catabolism, by increased synthesis or
uptake, or by some combination of these. ER stress is known
to impair the secretion of very low-density lipoprotein (VLDL)
from the liver (Ota et al., 2008; Rutkowski et al., 2008; Wang
et al., 2012; Yamamoto et al., 2010). VLDL particles are assem-
bled in the ER by the coalescence of triglyceride and cholesterol
around the ER client protein apolipoprotein B100 (Gibbons et al.,
2004). Failure to secrete triglycerides in the form of VLDL parti-
cles doubtless contributes to stress-induced hepatic steatosis.
ER stress in the liver also leads to substantial and coordinated
regulation of genes involved in lipid metabolism, including both
anabolism and catabolism (Arensdorf et al., 2013a; Rutkowski
et al., 2008). However, the contributions of lipogenesis and fatty.
creativecommons.org/licenses/by-nc-nd/4.0/).
acid oxidation (FAox) in vivo are not known, since the actual
activity of these pathways has not been assessed. Importantly,
ER stress has been implicated in a number of chronic diseases
that result in lipid dysregulation, including obesity (O¨zcan et al.,
2004), alcoholism (Ji, 2014), viral hepatitis (Chan, 2014), and
others. Thus, the mechanisms leading from ER stress to lipid
dysregulation are of considerable physiological importance.
ER stress is sensed by three pathways, and two of these—
mediated by PERK (PKR-like ER kinase) and IRE1a (Inositol-
requiring enzyme 1a)—are essential in vertebrates (Harding
et al., 2001; Zhang et al., 2011). However, animals lacking the
third sensor, ATF6a (Activating transcription factor 6a), are
viable and overtly normal (Gomez et al., 2014). ATF6a augments
the transcriptional upregulation of ER chaperones and ERAD
factors but is not strictly essential for the upregulation of most
of these (Adachi et al., 2008; Wu et al., 2007; Yamamoto et al.,
2007). Accordingly, cells lacking ATF6a are capable of initially
responding appropriately to ER stress but become progressively
impaired as ER stress persists, due to their inability to resolve
the stress (Wu et al., 2007). As a consequence, animals lacking
ATF6a, while having no apparent basal phenotype, are sensitive
to a number of experimental ER stressors (Azuma et al., 2014;
Cao et al., 2013; Egawa et al., 2011; Usui et al., 2012; Wu
et al., 2011; Yoshikawa et al., 2015). This sensitivity includes
challenge with TM, which, in Atf6a/ animals, leads to not
only profoundly fatty liver but also to fat accumulation in the
kidney (renal steatosis)—which occurs much less prominently,
if at all, in wild-type animals—and eventually, within 72–96 hr,
to death (Wu et al., 2007). We used the Atf6a/ animals, hyper-
sensitive to stress, as a tool to identify the pathways by which ER
stress leads to lipid accumulation in these two distinct organs.
RESULTS
ER Stress Induces Lipid Accumulation in Liver and
Kidneys of Atf6a/ Mice
To better characterize ER stress-induced hepatic and renal
steatosis, we treated wild-type and Atf6a/ mice with the
ER stressor TM. While other stressors, such as hepatic overex-
pression of a difficult-to-fold protein or proteasome inhibition,
also lead to steatosis and similar changes in the expression of
metabolic genes as TM (Chikka et al., 2013; Rutkowski et al.,
2008), TM is the most robust and specific ER stressor in vivo.
TM robustly targets the liver and kidneys, as shown by splicing
of the target of the IRE1 endonuclease, Xbp1mRNA (Figure 1A).
In our previous work, we showed that TM treatment leads to
hepatic lipid accumulation as rapidly as 8 hr after challenge (Are-
nsdorf et al., 2013a). Here as well, TM led to hepatic triglyceride
accumulation in both wild-type and Atf6a/ animals, and this
accumulation became even more pronounced specifically in
Atf6a/ animals at later times after challenge. This accumula-
tion was seen in both direct measurement of hepatic triglyceride
(Figure 1B) and immunostaining for the lipid droplet marker pro-
tein ADRP (Figure 1C). Thus, hepatic steatosis initially occurs in
both wild-type and Atf6a/ animals but is exacerbated at later
times in the knockouts.
In contrast to the liver, TM-induced renal lipid accumulation
was restricted to Atf6a/ animals. Oil red O staining, which de-tects neutral lipids, revealed very little accumulation in wild-type
animals but it did reveal substantial steatosis in the tubule cells in
Atf6a/ animals, particularly 48 hr after challenge (Figure 1D).
These findings were mirrored by ADRP immunostaining of the
kidneys (Figure 1E).
Lipogenesis Does Not Contribute to Early Hepatic
Steatosis
Previous reports in cultured hepatocytes and other cell types
have suggested that ER stress stimulates lipogenesis (Colgan
et al., 2007; Lee et al., 2012). However, our own work has sug-
gested that important genes of the lipogenic pathway are down-
regulated by ER stress (Arensdorf et al., 2013a), consistent with
other studies suggesting an anti-lipogenic effect of ER stress
(Herrema et al., 2016; Wang et al., 2012). Despite this finding,
it is possible that stress stimulates lipogenesis only during a
transient window that has been previously overlooked. Thus,
we first examined in wild-type and Atf6a/ animals the expres-
sion of genes encoding both transcriptional master regulators
of lipogenesis and cholesterologenesis (Srebf1, Srebf2, respec-
tively) and the important and rate-limiting enzymes in both pro-
cesses (Acaca, Fasn, Scd1, and Hmgcr). The lipogenic genes
(Srebf1, Acaca, Fasn, and Scd1) were robustly suppressed by
ER stress to comparable extents in both wild-type and Atf6a/
animals at all time points examined (Figure 2A). The cholestero-
logenic genes (Srebf2 and Hmgcr) were somewhat discrepant
between the two genotypes but did not show any evidence of
being upregulated (Figure 2A).
We next directly assessed lipogenic activity at early and
later points after ER stress induction, monitoring the conversion
of 14C-acetate into 14C-fatty acid by liver homogenates. We
monitored metabolic activity at both early time points (8 hr)
in wild-type animals and at later points in both wild-type and
Atf6a/ animals, when the latter specifically begin to show
both exacerbated liver ER stress and enhanced hepatic steato-
sis (e.g., Figure 1B; (Arensdorf et al., 2013a). As a positive con-
trol, we first confirmed that treating animals with insulin yielded
the expected increase in lipogenic activity (Jones, 2016) (Fig-
ure 2B). However, no significant increase in lipogenic activity
was seen in wild-type mice (Figure 2C) or Atf6a/ mice (data
not shown) 8 hr after challenge or in wild-type mice 24 hr after
challenge (Figure 2D). We did, however, detect an increase in
lipogenic activity in Atf6a/ animals 24 hr after challenge (Fig-
ure 2E). Given the substantial suppression of lipogenic genes
in these animals (Figure 2A), this finding was unexpected and
awaits further studies to explain. In any case, these results sug-
gest that lipogenesis is not a meaningful early contributor to ER
stress-induced hepatic steatosis in wild-type mice, although it
might contribute at a later phase.
ER Stress Suppresses Hepatic FAox
We next used a similar genetic and biochemical approach to
ask whether FAox contributes to hepatic steatosis. We found
that the transcriptional master regulator of FAox, Peroxisome
Proliferator Activated Receptor Alpha (Ppara), was suppressed
2-fold by ER stress in wild-type animals, while it was sup-
pressed 8-fold in Atf6a/ animals (Figure 3A). Genes encod-
ing key steps in beta-oxidation (Cpt1a, Acadm), peroxisomalCell Reports 19, 1794–1806, May 30, 2017 1795
Figure 1. TM Treatment Causes Hepatic and Renal Steatosis in Atf6a/ Mice
(A) Mice were challenged with vehicle or 1 mg/kg TM as indicated for 8 hr, and RNA was prepared from liver and kidneys. Xbp1mRNA splicing was detected by
conventional RT-PCR, with spliced (sp) and unspliced (us) forms indicated.
(B) Wild-type or Atf6a/mice were challenged with vehicle or 1 mg/kg TM, and triglyceride levels were measured in liver lysates at the indicated times following
injection. Significances compare Atf6a/ and wild-type (w.t.) TM-treated animals. n = 3–4 animals per group. Throughout the article, graphs present data as
means ± SD. **p < 0.01.
(C) Formalin-fixed liver sections from wild-type or Atf6a/ animals treated with TM for 48 hr were stained for the lipid droplet marker protein ADRP. Repre-
sentative images are shown. Scale bars, 50 mm.
(D) Fresh frozen kidney sections fromwild-type orAtf6a/ animals treated for 24 or 48 hr with TMwere stainedwith the neutral lipid stain oil redO. Representative
images are shown. Scale bars, 50 mm.
(E) Formalin-fixed kidney sections from animals treated as in (D) were stained for the lipid droplet marker protein ADRP as in (C). Representative images are
shown. Scale bars, 50 mm.
NT, not treated.oxidation (Acox1), and microsomal oxidation (Cyp4a10) were
not suppressed in wild-type animals but were significantly sup-
pressed in Atf6a/ animals (Figure 3A).
To directly assess FAox activity, we monitored the conver-
sion of 14C-palmitate into 14CO2; as expected, this conversion1796 Cell Reports 19, 1794–1806, May 30, 2017was significantly reduced by the CPT1 inhibitor etomoxir (ET)
(Figure 3B). Using this assay to monitor FAox activity in liver
homogenates, we found that FAox was suppressed by approx-
imately 50% in wild-type animals 8 hr after challenge (Fig-
ure 3C). Supporting this finding, serum levels of the ketone
Figure 2. TM Suppresses Lipogenic Genes and Does Not Affect Hepatic Lipogenic Activity at Early Times after Challenge
(A) The expression of the indicated lipogenic and cholesterologenic genes wasmeasured by qRT-PCR from the livers of wild-type orAtf6a/ animals challenged
with TM for the indicated times. Significances were determined relative to unchallenged animals of the same genotype. n = 3.
(B) Wild-type mice were treated with 2 U human insulin for 1 hr, and lipogenic activity relative to homogenate protein concentration was measured in liver
homogenates by conversion of 14C-acetate into 14C-fatty acid as described in Experimental Procedures. n = 3.
(C) Wild-type (w.t.) mice were treated with TM for 8 hr, and hepatic lipogenic activity was measured as in (B). n = 3.
(D) Wild-type mice were treated with TM for 24 hr, and then lipogenic activity was assessed as described earlier. n = 3.
(E) Same as in (D), except using Atf6a/ animals. n = 3.
*p < 0.05; **p < 0.01; NS, not significant; NT, not treated; CPM, counts per minute.body b-hydroxybutyrate, which is a by-product of hepatic FAox
(Rui, 2014), were also diminished (Figure 3D). By 48 hr after chal-
lenge, FAox activity returned to normal levels in wild-type mice
but remained suppressed in Atf6a/ animals (Figure 3E).
Lipid accumulation due to impaired FAox could be due to
dysregulation of b-oxidation in the mitochondria, to the inhibi-
tion of peroxisomal oxidation—which principally shortens very
long chain fatty acids for entry into b-oxidation—or to both.
We observed a significant decrease in the ability of isolated
mitochondria from TM-treated Atf6a/ animals to completely
oxidize palmitate to CO2 (Figure 3F). Instead, mitochondria
from TM-treated animals accumulated acid-soluble metabolites,
which are incompletely oxidized products of b-oxidation (Hir-
schey et al., 2011) (Figure 3G). The accumulation of these
products suggests that TM impairs FAox at a point downstream
of lipid shuttling into mitochondria and upstream of entry of
acetyl-CoA (coenzyme A) into the tricarboxylic acid (TCA) cycle.
Mitochondrial content did not differ between groups, as as-
sessed by oxidative phosphorylation (OXPHOS) immunoblot
(data not shown). We also observed that peroxisomal content
was dramatically reduced in Atf6a/, but not wild-type, animals
24 hr after challenge (Figure 3H). This finding was consistent withthe profound genetic suppression of Ppara, which, as its name
denotes, stimulates peroxisome proliferation. Taken together,
these results show that ER stress inhibits FAox activity, likely
at both mitochondrial and peroxisomal levels, and that this inhi-
bition contributes to the early development of hepatic steatosis
in both wild-type and knockout animals and to the late aggrava-
tion of hepatic steatosis in Atf6a/ animals.
Neither Suppressed Catabolism nor Enhanced
Anabolism Accounts for Kidney Steatosis
Given that liver-autonomous processes—namely, inhibition of
VLDL secretion (Ota et al., 2008; Rutkowski et al., 2008;
Wang et al., 2012; Yamamoto et al., 2010) and of FAox (Fig-
ure 3)—contribute to stress-induced hepatic steatosis, we asked
whether renal steatosis might, likewise, occur through direct
regulation of metabolism by ER stress in the kidney. Supporting
our findings in Figure 1, we found that mRNA expression of the
lipid droplet marker Adrp—the transcription of which is known
to increase when intracellular lipid levels rise (Targett-Adams
et al., 2005)—was increased in Atf6a/ mice, but not wild-
type mice, and that this induction was much more dramatic
48 hr after challenge (Figure 4A). Thus, by at least this readout,Cell Reports 19, 1794–1806, May 30, 2017 1797
Figure 3. ER Stress Suppresses Hepatic FAox Activity
(A) Expression of the indicated FAox genes was assessed by qRT-PCR as in Figure 2A.
(B) Mice were fasted for 24 hr, and homogenates were isolated and divided into two aliquots, one of which was treated with the CPT1 inhibitor (inhib.) etomoxir
(ET). FAox activity was measured as described in the Experimental Procedures. n = 6.
(C) Wild-type (w.t.) mice were fasted for 24 hr and treated with TM for the final 8 hr, and FAox activity was measured from liver homogenates as described earlier.
n = 6–8.
(D) b-hydroxybutyrate levels were measured from the plasma of animals treated as in (C). n = 8–9.
(E)Wild-type orAtf6a/ animals were treated for 48 hr with TM, including fasting for the last 20 hr. Hepatic FAox activity wasmeasured as described earlier. n = 3.
(F and G) Atf6a/ animals were treated for 48 hr with TM, and mitochondria were isolated from liver homogenates. Production of 14CO2 (F) and acid-soluble
metabolites (G) was measured as described in Experimental Procedures. n = 4.
(H) Peroxisome abundance was assessed by immunohistochemistry, using the marker PMP70, from animals treated for 24 hr with vehicle or 1 mg/kg TM.
Representative data are shown. Scale bars, 20 mm.
*p < 0.05; **p < 0.01; ***p < 0.001; NT, not treated; CPM, counts per minute.
1798 Cell Reports 19, 1794–1806, May 30, 2017
Figure 4. TM Treatment Does Not Alter Renal FAox or Lipogenic Activity
(A) qRT-PCR was used to assess the relative mRNA expression of the gene encoding the lipid droplet marker protein ADRP in kidneys of wild-type or Atf6a/
animals treated for 24 or 48 hr with TM. *p < 0.05; **p < 0.01.
(B) Same as (A), except assessing expression of a representative sampling of metabolic genes regulating lipogenesis, cholesterologenesis, and FAox.
(C) FAox activity was measured as in Figure 3E, except using kidney homogenates. No significant differences were seen. n = 3. w.t., wild-type.
(D) Lipogenic activity was measured in Atf6a/ animals as in Figure 2E. No significant differences were seen. n = 3.
NT, not treated; CPM, counts per minute.there is transcriptional evidence of lipid dysregulation in the kid-
ney. In contrast to the liver, however, a survey of genes involved
in both lipogenesis and FAox revealed no significant changes in
the kidney in either wild-type or knockout animals (Figure 4B;
data not shown). Consistent with this finding, we observed no
evidence that either FAox (Figure 4C) or lipogenesis (Figure 4D)
was altered in the kidneys of Atf6a/mice, despite their exten-
sive steatosis.
Lipid Mobilization from Adipose Likely Drives Late
Hepatic and Renal Steatosis in Atf6a/ Animals
Lacking direct evidence for altered lipid catabolism or anabolism
in renal steatosis, we utilized an untargeted lipidomic approach
with the goal of identifying potential pathways of lipid meta-
bolism that might be dysregulated in Atf6a/ animals and could
underlie the steatosis phenotype. We also reasoned that this
approach could identify lipid species other than the neutral lipids
that are detected by oil red O staining and ADRP immunostain-
ing, in the event that the effects of ER stress on lipid meta-
bolism in these animals extend to other pathways. To do this,
we challenged wild-type or knockout animals with TM for
48 hr, extracted lipids from kidney homogenates, and analyzed
them by liquid chromatography-mass spectrometry (LC-MS) inboth positive and negative modes (i.e., for the separation of an-
ions or cations generated by electrospray ionization (ESI), with
each mode preferentially detecting different classes of lipids).
Resultant data were then processed using XCMS software to
categorize and putatively identify altered lipid species.
Cloud plots of this analysis are shown in Figure 5, and putative
lipid identifications are listed in Table 1. Consistent with the
observation that wild-type animals accumulated very little renal
fat upon TM treatment, these animals displayed comparable
numbers of lipid species that were enhanced (Figure 5A, green
circles) versus reduced (Figure 5, red circles) in the positive ion
mode. In contrast, in response to TM treatment, Atf6a/ ani-
mals displayed an enhanced abundance of a wide spectrum of
lipid species, with particular enrichment for triglycerides and
ceramides (Figure 5B; Table 1). The accumulation of triglycerides
is consistent with enhanced lipid storage, but it shed little
light on the source of those lipids, since lipid accumulation in
this case was best explained by small accumulations of many
diverse lipid species, rather than unique accumulation of one
or a few such species. The accumulation of ceramides was
accompanied by the upregulation of Sptlc1, which encodes
the rate-limiting enzyme in ceramide synthesis, and also by
enhanced TUNEL staining indicative of cell death, known to beCell Reports 19, 1794–1806, May 30, 2017 1799
Figure 5. TM Treatment Leads to Quantifiable Lipid Accumulation in the Kidneys of Atf6a/ but Not Wild-Type Animals
(A–D) LC-MS in both positive and negative ion modes was used to profile the lipid distribution upon TM challenge in wild-type and Atf6a/ animals. (A) and (B)
show positive mode, and (C) and (D) show negative mode. The response in wild-type animals is shown in (A) and (C), while the response in Atf6a/ animals is
shown in (B) and (D). XCMS software was used to generate cloud plots to provide a global view of species that were significantly different between groups. The
x axis shows retention time, and the y axis shows the mass-to-charge (m/z) ratio, with species upregulated by TM shown in green above the midline and
downregulated species shown in red below the midline. The species shown are all those with a maximum intensity above 5,000 (i.e., to filter for reasonably
abundant species) and an FDR-adjusted p value below 0.01. Darker circles have lower (i.e., more significant) p values, and the radius of each feature is pro-
portional to the fold change. Position of FFAs is indicated. n = 4.
NT, not treated. See also Figure S1.associated with elevated ceramides (Mather and Siskind, 2011;
Ueda, 2015) (Figure S1). This finding suggests that ceramide
synthesis is actively regulated by prolonged ER stress in the
kidney—a finding that awaits mechanistic investigation.
Analysis in negative ion mode immediately suggested a po-
tential pathway to lipid accumulation. Very few lipid species
detected in this mode were changed by TM in wild-type animals
(and of these, none could be putatively identified) (Figure 5C;
Table 1). However, Atf6a/ animals evinced a substantial accu-
mulation of free fatty acids (FFAs) (Figure 5D; Table 1). As FFAs
are not the preferred form of cellular lipid storage and can, in fact,
be lipotoxic (Neuschwander-Tetri, 2010), this finding suggested
that the production (by lipogenesis or hepatic lipolysis) or import
of FFAs outpaced the capacity of the kidneys to esterify them.
In order to confirm this accumulation of FFAs, the absolute
concentrations of stearic, palmitic, oleic, and linoleic acids
were quantified by comparison to standards. This analysis
showed a significant accumulation of palmitic acid and even
greater accumulations of oleic and linoleic acids (Figure 6A).
The apparent preference for the accumulation of unsaturated
fatty acids (FAs) might account for the similar accumulation of tri-
glycerides with unsaturated FA chains (Table 1). These findings1800 Cell Reports 19, 1794–1806, May 30, 2017raised the possibility that the accumulation of FFAs might also
contribute to liver steatosis in Atf6a/ animals. Indeed, 48 hr
after TM treatment, there was a dramatic increase in FFAs
in Atf6a/ animals, to the point that these were among the
most abundant negative-mode lipids in the liver (Figure 6B). In
contrast, there was no significant difference in FFAs in the livers
of these animals 24 hr after treatment (data not shown), indi-
cating that FFA accumulation is a late event.
The late accumulation of FFAs in both the liver and kidneys of
Atf6a/ animals, as well as the absence of evidence for altered
renal lipid anabolism or catabolism in these animals, led us to
consider the possibility that this process is driven by lipolysis
from adipose tissue. At early times after challenge, TM did not
elicit a change in plasma levels of non-esterified fatty acids
(NEFAs) (Figure 6C). In wild-type animals, this remained the
case through later times (Figure 6D). However, Atf6a/ animals
showed elevated plasma NEFA levels 48 hr after challenge, to an
extent comparable to that elicited by prolonged fasting in wild-
type animals (Figure 6D).
These results led us to suspect that unmitigated ER
stress might suppress food consumption and drive fasting-
induced lipolysis. Analysis of animals housed in metabolic cages
Table 1. Putative Lipid Identifications from LC-MS Analysis of the Kidney
Putative ID Fold p Level m/z Retention Time (min)
Regulated by TM in the Kidney, Wild-Type Animals, POSITIVE Mode
PC (38:3) 2.3 0.0013 36,410 812.62 46.3
PE (P-40:5) 3.2* 0.0065 7,578 778.57 46.5
54:8 TG 1.6 0.0084 25,736 892.75 51.7
48:3 TG 1.6 0.0043 50,195 818.73 52.4
50:4 TG 3.5 0.0000 71,882 844.74 52.9
PC (P-38:6) 2.0* 0.0034 5,092 790.57 56.1
TG (48:0) 1.5 0.0068 20,852 824.78 58.3
Regulated by TM in the Kidney, Atf6a/ Animals, POSITIVE Mode
Linoleyl carnitine 2.1* 0.0002 13,944 424.34 29.0
Palmitoyl carnitine 1.6* 0.0013 16,189 400.34 29.7
Lyso-PAF C-16 3.0* 0.0065 6,483 482.36 36.8
PC (32:2) 4.5* 0.0027 38,593 730.54 44.3
PA (42:4) 2.8* 0.0020 20,999 781.56 44.3
PC (32:1) 2.1* 0.0046 154,864 732.56 45.0
PC (32:0) 2.1* 0.0051 18,978 734.56 45.0
PE (38:3) 2.2* 0.0024 7,374 770.58 45.1
PS (36:0) 2.1 0.0058 22,716 809.59 45.5
PS (38:1) 1.7 0.0093 15,486 835.61 46.0
PA (P-42:0) 1.7* 0.0067 14,692 773.65 46.8
CerP(d44:2) 2.3* 0.0070 5,808 801.68 46.9
GalCer(d40:2) 1.9* 0.0036 30,998 799.67 46.9
Behenyl linolenate 2.2* 0.0008 13,605 604.60 47.6
TG (52:6) 3.8* 0.0092 45,386 868.74 52.3
TG (54:8) 9.4* 0.0010 21,330 892.75 52.6
TG (58:9) 7.2* 0.0054 6,584 946.79 53.4
TG (58:8) 3.1* 0.0095 6,079 948.81 54.7
TG (54:6) 2.3* 0.0051 15,588 896.78 56.1
TG (56:6) 3.8* 0.0007 16,561 924.81 56.2
TG (56:7) 4.9* 0.0038 24,642 922.79 56.2
Regulated by TM in the Kidney, Wild-Type Animals, NEGATIVE Mode
None identified
Regulated by TM in the Kidney, Atf6a/ Animals, NEGATIVE Mode
C16:2 Fatty acid 11.7* 0.0081 6,994 251.20 24.5
C18:3 Fatty acid 7.7* 0.0081 9,365 277.22 25.3
C16:1 Fatty acid 9.9* 0.0073 23,028 253.22 25.4
C18:2 Fatty acid 8.7* 0.0042 159,391 279.23 26.2
C18:0 Fatty acid 2.1* 0.0058 6,731 283.24 26.6
C16:0 Fatty acid 2.2* 0.0059 159,497 255.23 26.7
C18:1 Fatty acid 7.9* 0.0024 140,480 281.25 27.3
C20:1 Fatty acid 9.8* 0.0041 8,325 309.28 28.9
Cer(d34:2) 3.2* 0.0003 31,934 534.49 45.0
Cer(d34:1) 2.5* 0.0002 50,804 536.50 45.6
Cer(d40:2) 2.5* 0.0053 21,262 618.58 47.2
Asterisks indicate upregulation by TM. m/z, mass-to-charge ratio; PE, phosphatidylethanolamine; PC, phosphatidylcholine, PA, phosphatidic acid;
TG, triglyceride; PAF, platelet activating factor; PS, phosphatidylserine; GalCer, galactoyslceramide; CerP, ceramide phosphate; Cer, ceramide.supported this hypothesis: TM treatment significantly reduced
food intake in both wild-type and Atf6a/ animals, and this
reduction was exacerbated by 48 hr selectively in Atf6a/ ani-mals (Figure 6E). Consistent with this finding, by 48 hr, Atf6a/
mice were severely hypoglycemic (Figure 6F). That this hypogly-
cemia was likely due to anorexia and not to hyperinsulinemiaCell Reports 19, 1794–1806, May 30, 2017 1801
Figure 6. TM Treatment Increases Renal and Hepatic FFA Levels Preferentially in Atf6a/ Animals
(A) Renal levels of stearic, palmitic, oleic, and linoleic acids were quantified from LC runs of extracted lipids following 48 hr of TM treatment in wild-type (w.t.) or
Atf6a/ animals. n = 4.
(B) Total ion chromatograms are shown from LC runs of hepatic lipids following 48 hr of TM treatment in wild-type or Atf6a/ animals. Retention time of FFAs is
indicated. Each chromatogram shows a single representative animal.
(C) NEFAs were measured from plasma of wild-type animals fasted for 24 hr and treated for 8 hr with TM or vehicle. n = 8–9.
(D) NEFAs were measured from plasma of wild-type or Atf6a/ animals treated for 24 or 48 hr with TM. As a comparison, wild-type animals were also fed ad
libitum or fasted for 24 hr. n = 3–6.
(E) Wild-type or Atf6a/ animals were habituated to metabolic cages, and food intake was measured either for the day preceding TM treatment (day 0) or for the
periods 0–24 hr (day 1) or 24–48 hr (day 2) thereafter. Statistical significance comparing day 1measurements to day 2measurements was calculated using paired
t tests, while significance comparing wild-type to Atf6a/ animals on day 2 used one-way ANOVA. n = 6–7.
(F) Plasma glucose levels were measured 48 hr after TM challenge in animals from (E).
*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant.
NT, not treated; CPM, counts per minute. See also Figure S2.from stress-dependent pancreatic beta cell proliferation (Sharma
et al., 2015) was supported by the observation thatAtf6a/mice
did not become hyperinsulinemic during TM treatment (Fig-
ure S2B) but, if anything, tended toward hyperglycemia rather1802 Cell Reports 19, 1794–1806, May 30, 2017than hypoglycemia under unchallenged conditions (Figure S2C).
It is also unlikely that lipolysis was driven by direct effects of
TM on adipose, as we found no evidence that TM elicited ER
stress in either subcutaneous or visceral white adipose deposits
(Figure S2D). These data point to anorexia-induced lipolysis as a
potentially significant contributor to the late accumulation of
FFAs in both the liver and kidneys of Atf6a/mice.
DISCUSSION
Our results suggest that ER stress has both cell-autonomous
and cell-non-autonomous effects on peripheral lipid meta-
bolism, with several pathways contributing to the accumulation
of lipid in the liver and kidneys. In the liver, ER stress elicited
the relatively rapid (within 8 hr) inhibition of FAox. While this
inhibition was alleviated in wild-type animals, it persisted and
was possibly exacerbated in Atf6a/ animals. This persistence
corresponded with the ongoing ER stress burden—owing to an
inability to effectively harness the UPR to alleviate the stress
(Wu et al., 2007; Yamamoto et al., 2007)—and with the profound
suppression of FAox genes in these animals. Thus, we conclude
that the inhibition of FAox likely contributes to stress-induced
hepatic steatosis. This contribution would be in addition to the
already described inhibition of VLDL secretion that would be
expected to impair the efflux of triglyceride. This effect appears
also to be liver specific, as we found no evidence for either ge-
netic or biochemical inhibition of FAox in the kidney (Figure 4).
We have previously shown that the inhibition of FAox protects
ER function by enhancing the oxidative potential of the ER, which
must generate disulfide bonds on nascent proteins (Tyra et al.,
2012). It is tempting to speculate that the direct regulation of
FAox represents an underappreciated mechanism by which
the UPR protects ER homeostasis.
While lipogenesis has been proposed to contribute to ER
stress-induced hepatic steatosis, based on studies in cultured
hepatocytes (Lee et al., 2012), we found little evidence here
that it is a significant contributor in vivo, at least at early times.
There is, perhaps, an increase in lipogenic activity at later time
points selectively in Atf6a/ animals, although this observation
is difficult to reconcile with the substantial suppression of both
Srebf genes and of those encoding the key enzymes of lipogen-
esis. Thus, its potential role remains ambiguous. In the kidney,
there was no evidence that lipogenesis contributed to fat accu-
mulation, although we note that a previous report that suggested
that ER stress causes renal lipid accumulation through an
SREBP2-dependent mechanism (Lhota´k et al., 2012). SREBP2
drives cholesterologenesis (Sato, 2010), and although Hmgcr
(encoding the rate-limiting step in cholesterol biosynthesis)
was not elevated by TM treatment, the lipogenesis assay used
here does not extract cholesterol, making it still possible that
SREBP2-dependent cholesterologenesis contributes to renal
steatosis.
The other major contributor to both hepatic and renal steatosis
appears to be anorexia-induced lipolysis. Indeed, the dramatic
increase in both hepatic and renal FFAs at 48 hr was the most
unexpected finding of the lipidomic analysis. The evidence that
Atf6a/ animals preferentially showed reduced food intake,
hypoglycemia, and elevated plasma NEFA levels supports the
idea that late lipid accumulation arises cell non-autonomously
as a consequence of anorexia, particularly in the kidney. These
elevated FFAs are presumably taken up by both organs, and
some of it (though clearly not all) is esterified into triglyceride.However, we note that the rate of fatty acid uptake into the liver
and kidney was not measured, since this measurement in vivo is
complicated by both the instability and the rapid oxidation of
labeled FFA probes (Henkin et al., 2012). A survey of the expres-
sion of fatty acid transport genes in liver and kidney revealed
some that were suppressed by stress and others that were unaf-
fected (data not shown), technically leaving open the question of
whether the elevated levels of FFAs seen here, in fact, lead to
increased renal and hepatic FFA levels. In any case, it will be
interesting to determine whether the observed starvation and
resultant lipolysis occurs merely as a result of Atf6a/ animals
experiencing severe illness due to kidney and/or liver dysfunc-
tion or whether, instead, there are effects of TM administration
on tissues other than the liver and kidney in these animals that
drive lipolysis. For instance, it is also possible that lipolysis is
driven by the effects of ATF6a deletion in white adipose,
although the fact that we did not find evidence of TM-induced
ER stress in the adipose (Figure S2D) makes this possibility
somewhat unlikely.
Ultimately, the reason that Atf6a/ animals eventually suc-
cumb to TM challenge (Wu et al., 2007), while wild-type animals
do not, remains unclear. Given that Atf6a/ animals show
evidence of cell death in the kidney (Figure S1B), one possibility
is that unmitigated ER stress in the Atf6a/ kidney damages
the organ beyond repair through extensive apoptosis and/or
necrosis. Indeed, one of the other notable features of our lipi-
domic analysis was the elevation of several species putatively
identified as ceramides (Table 1), which are known mediators
of cell-death pathways and serve as biomarkers for renal injury
(Mather and Siskind, 2011; Ueda, 2015). We also favor the
kidney as the most probable primary site of TM-induced
anorexia in Atf6a/ mice, in part because the liver—the other
organ most clearly targeted by TM—while clearly adversely
affected by ER stress in these animals, is so resilient to lipid
accumulation and cell loss (Forbes and Newsome, 2016). In
sum, the data here are most consistent with a model in which
ER stress in the liver directly regulates lipid metabolism in the
organ, while unmitigated ER stress in the kidney and/or liver
drives lipolysis from the white adipose to further dysregulate
metabolism in these organs. If this is the case, then it is
possible that physiological ER stress localized in a given tissue
can, nonetheless, drive lipid dysregulation in other sites not
directly experiencing ER stress. Ultimately, the tissue-specific
deletion of ATF6a will be needed to address the relative con-
tributions of liver, kidney, and other organs to the extreme
sensitivity of Atf6a/ animals to TM and to determine how
the ER stress signaling network interacts with other regulators
of metabolism, such as CREBH (Zhang et al., 2012) and CRTC2
(Wang et al., 2009).
Although other stressors, such as proteasome inhibition or
secretory protein overexpression, also lead to hepatic steatosis
and similar changes in gene regulation, at least in the liver—
making it unlikely that the effects seen here are specific to TM
per se—the agent is, nonetheless, probably a much harsher
stimulus than those that lead to lipid dysregulation in vivo.
Thus,moving forward, it will be important to determine the extent
to which more physiological ER stresses impinge upon lipid
metabolism in the ways described here.Cell Reports 19, 1794–1806, May 30, 2017 1803
EXPERIMENTAL PROCEDURES
Mice
Animals were housed in a pathogen-free facility under climate controlled con-
ditions with a 12 hr light/dark cycle, and were maintained on standard rodent
chow. All procedures were approved by the University of Iowa Institutional An-
imal Care and Use Committee. Atf6a/ animals have been backcrossed into
the C57BL/6J strain for more than ten generations. Eight-to-10 week-old ani-
mals of both genders were injected intraperitoneally with either 1 mg/kg TM
(EMD) dissolved in DMSO and diluted in 150 mM dextrose or PBS or an equiv-
alent concentration of DMSO alone in dextrose or PBS (for all non-treated an-
imals). At sacrifice, plasma was collected, and liver and kidney tissues were
harvested andwere either used fresh (for biochemical assays), fixed in formalin
(for immunostaining), frozen in OCT (for oil red O staining), or flash frozen in
liquid N2 (for molecular analysis and MS). Tissue triglyceride measurement
(Arensdorf et al., 2013a), immunostaining (Chikka et al., 2013), oil red O stain-
ing (Arensdorf et al., 2013a), and qRT-PCR (Rutkowski et al., 2006) were
performed as described. For metabolic cage experiments, animals were habit-
uated to cages for 5 days and then treated with 1 mg/kg TM and monitored for
a further 2 days.
Lipogenesis Assay
Lipogenesis assays were performed on fresh tissue homogenates, modifying a
protocol described by Harada et al. (2007). Briefly, liver was placed on ice, and
60 mg was macerated into small pieces and added to 2 mL DMEM, which had
been aerated in 5% CO2/95% O2 for 20 min. 6 mCi of [1-
14C] sodium acetate
was added, and samples were incubated for 90 min at 37C in 5% CO2/95%
O2. The tissue was removed, dabbed with an absorbent wipe, and added to
300 mL of 30% w/v KOH heated to 70C, with agitation for 10 min; then 300 mL
100% ethanol was added prior to continued incubation at 70C, with agitation
for 2 hr. At this point, protein concentration wasmeasured from an aliquot, while
the remainder of the sample was chilled on ice and then acidified with 300 mLof
9MH2SO4. Lipidswere extracted three timeswith 500mL light petroleum (boiling
point [bp], 40C–60C). The petroleum fractions were combined and washed
three times with deionized water. They were then evaporated to dryness under
nitrogen gas and then dissolved in scintillation fluid for 14C quantification. For
8-hr TM treatment, animals were also treatedwith 2 U human insulin intraperito-
neally to ensure that conditions favored lipogenesis activity.
FAox Assays
FAox assays were performed on fresh tissue generally, as described previ-
ously (Hirschey and Verdin, 2010), in animals fasted for 24 hr to ensure that
conditions favored FAox activity. Briefly, 150 mg tissue was added to 1 mL
ice-cold STE Buffer (0.25 M sucrose, 10 mM Tris (pH 7.4), 1 mM EDTA),
and the tissue was homogenized in a dounce homogenizer. The homogenate
was centrifuged at 4C for 10 min at 4203 g. A portion of the supernatant was
reserved to determine protein concentration. 20 mL of the supernatant was
added to 355 mL reaction mixture (100 mM sucrose, 10 mM Tris (pH 7.4),
5 mM KH2PO4, 0.2 mM EDTA, 0.3% FFA-free BSA, 80 mM KCl, 2 mM L-carni-
tine, 0.1 mMmalic acid, 0.05 mMCoA, 1mMMgCl2, with 1 mMDTT and 2mM
ATP added fresh). Then 25 mL of a mixture containing 0.1 mM palmitic acid,
7.5% fatty-acid-free BSA, and 4 mCi of [1-14C] palmitic acid was added, and
the reaction was incubated with agitation at 37C for 60 min. Following incu-
bation, the samples were transferred to new tubes containing 200 mL of 1 M
perchloric acid fitted in the lid with Whatmann 3-mm filter paper soaked in
1MNaOH. Sampleswere capped immediately and incubated at room temper-
ature for 1 hr, and then the filter paper discs were removed and transferred to
scintillation fluid for 14C quantification. Etomoxir was from Sigma. To measure
plasma b-hydroxybutyrate, the Ketone Body Assay Kit (Cayman Chemical)
was used.
For FAox in isolated mitochondria, mitochondria were isolated from
150 mg of fresh liver tissue using differential centrifugation as previously
described (Gray et al., 2016).14C-palmitate oxidation was measured as previ-
ously described (Sheldon et al., 2015). In brief, mitochondria were placed in an
air-tight well with reaction media containing 20 mM palmitate conjugated to
BSA. After 1 hr, 70% perchloric acid was injected into the well to liberate
14CO2, which was trapped in a microcentrifuge tube containing 1 N NaOH.1804 Cell Reports 19, 1794–1806, May 30, 201714CO2 containing NaOH and
14C acid-soluble metabolites (ASMs) were quan-
tified via liquid scintillation counting.Media-specific activity and blank samples
(no mitochondria) were used to convert raw dpm counts to micromole per
gram of protein per hour.
MS
For MS analysis, frozen tissue pieces were pulverized using a metal cup
and mallet. 100 mg frozen tissue powder was added to 2 mL of a 2:1 chloro-
form:methanol mixture in a 5-mL glass flat-bottom tube with a Teflon cap liner.
Heptadecanoic acid was spiked into the sample at 0.5 ng/mL as an internal
standard. The sample was sonicated on ice with a probe sonicator for 60 s;
then 1 mL of H2O was added, and the sample was vortexed for 30 s, incu-
bated on ice for 30 min, and revortexed. Following centrifugation for 15 min
at 200 3 g at 4C, the bottom layer was removed, transferred to a new tube,
dried under a stream of nitrogen gas, and resuspended in 200 mL of 2:1
chloroform:methanol.
The samples were analyzed by LC-MS using a Waters Q-TOF (quadrupole
time-of-flight) Premier mass spectrometer interfaced with an Acquity UPLC
(ultra-performance liquid chromatography) system. ESI was used, and data
were collected in both positive and negative ion modes using leucine enkeph-
alin as the lock mass. The MS conditions were as follows for both positive and
negative ESI: capillary voltage, 2.8 kV; sampling cone voltage, 35 V; source
temperature, 110C; desolvation gas temperature, 400C; cone gas flow,
30 L/hr; and desolvation gas flow, 750 L/hr. Data were collected over the
mass range, 130 to 1,000 Da.
The chromatographic separationwasperformedusing aPhenomenexGemini
C18 column (4.6 mm3 50 mm, 5 mm). The mobile phase was 95:5 water/meth-
anol (v/v) in solvent A and 65:35:5 isopropanol/methanol/water (v/v/v) in solvent
B. Depending on whether positive or negative ESI was being used, either
0.1% formic acid or ammonium hydroxide was added to both solvents, respec-
tively. The gradient initially held for 5 min at 100% solvent A at a flow rate of
100 mL/min. At 5.1 min, flow rate increased to 400 mL/min. Over the next
40 min, gradient increased to 100% solvent B, at which point, the flow rate
was increased to 500 mL/min. The system was held at 100% solvent B for
18minand then re-equilibratedback to 100%solvent A over 7min. Injection vol-
umewas 15 mL for all samples. The columnwas held at 25C throughout the run.
LC-MS data acquisition and analysis were performed by using Waters Mas-
sLynx software. The quantification of the fatty acids was performed utilizing
QuanLynx software package using standard curves for oleic, linoleic, palmitic,
and stearic acids. Otherwise, the data files were converted to NetCDF format
using DataBridge conversion software for further processing in XCMS. CDF
files were uploaded to the XCMS website (http://xcmsonline.scripps.edu) to
create individual datasets. The datasets were then compared using pairwise
analysis with the UPLC/Q-TOF parameter. The results table was filtered using
the following parameters: FDR (false discovery rate)-adjusted p value% 0.01,
fold R 1.5, and maximum intensity R 5,000. These same parameters were
applied to generate the red/green cloud plots. The mass-to-charge ratio
from the species that fit the parameters was entered into the Lipid Maps online
website search tool for the LIPID MAPS Structure Database (http://www.
lipidmaps.org/data/structure/) and Metlin, with the following parameters:
[M+NH4]+ and [M+H]+ (for positive run), [MH] (for negative run), mass toler-
ance of 0.1. The top hit was chosen for the lipid ID, after adjustment for the
most plausible adducts, given the LC conditions. For triglycerides, the top
hit that had all even chain carbons was chosen for the ID. Data are deposited
in the Metabolights database (http://www.ebi.ac.uk/metabolights/).
Statistics
Throughout the paper, error bars represent means ± SD. Unless indicated
otherwise, significance was calculated by one-way ANOVA with Tukey’s
post hoc where appropriate. Symbols to denote significance are as follows:
*p < 0.05; **p < 0.01; ***p < 0.001. For all animal experiments, n represents
the number of individual animals per group.
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